医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Heuron Participates in the Asian-Oceanian Congress of Neuroradiology (AOCNR) 2023

2023年08月17日 AM10:00
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea

Heuron, a medical artificial intelligence (AI) solution company (Donghoon Shin, CEO), announced its participation in the Asian-Oceanian Congress of Neuroradiology 2023 (AOCNR 2023), which will be held in Singapore from August 18th.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230816768554/en/

Heuron, a medical AI solution company, participates in the Asian-Oceanian Congress of Neuroradiology 2023 (AOCNR 2023), which is held in Singapore from August 18th. Heuron showcases its neurodegenerative disease AI solution such as Heuron AgingCare Suite, and its integrated stroke solution, Heuron StroCare Suite, to engage in global collaborations and partnerships. (Graphic: Business Wire)

Heuron, a medical AI solution company, participates in the Asian-Oceanian Congress of Neuroradiology 2023 (AOCNR 2023), which is held in Singapore from August 18th. Heuron showcases its neurodegenerative disease AI solution such as Heuron AgingCare Suite, and its integrated stroke solution, Heuron StroCare Suite, to engage in global collaborations and partnerships. (Graphic: Business Wire)

AOCNR is an international academic conference organized by the Asian Oceanian Society of Neuroradiology, gathering over a thousand medical professionals from Asia, Oceania, North America, Europe, and the rest of the world.

During this event, Heuron will showcase its neurodegenerative disease AI solution such as Heuron AgingCare Suite™, and its integrated stroke solution, Heuron StroCare Suite™, to engage in global collaborations and partnerships.

Heuron AgingCare Suite™ includes neurodegenerative diseases solutions for Parkinson’s disease (Heuron IPD and Heuron NI), and Alzheimer’s disease (Heuron AD and Heuron Brain PET). Utilizing MRI-based technology, it offers visual and quantitative information by aiding the early detection of neurodegenerative diseases and formulating an initial treatment plan.

Heuron StroCare Suite™ is an integrated AI solution that enables one-stop classification of patients with cerebral hemorrhage and cerebral infarction with non-contrast CT. Without the need for contrast agents, it analyzes and identifies emergent stroke patients with conditions ranging from cerebral hemorrhage to emergent large vessel occlusion and calculates ASPECT score, ensuring a fast medical decision-making for patients requiring urgent procedures to reduce treatment time.

Donghoon Shin, CEO of Heuron, stated, “We are seeing significant interests in Heuron products from Asian countries, and actively expanding our business presence. At the AOCNR 2023, we aim to strongly enhance competitiveness of our products, and seek partnerships with various institutions and medical professionals through research collaborations, demo presentations, and more.”

Heuron Co., Ltd.

Heuron is a medical AI software company for central nervous system diseases, founded in 2017 by Professor Shin Donghoon of Gachon University Gil Medical Center. It offers diagnostic AI software that automatically quantitatively analyzes neurodegenerative brain disorders’ medical images (MRI, PET, CT, etc.), including Parkinson’s disease, dementia, and strokes, to aid accurate and swift decision-making by medical professionals. Starting with the world’s first MRI-based Parkinson’s disease diagnostic AI software, ‘Heuron IPD,’ Heuron has developed over 20 product pipelines. It became the first in Korea to develop dementia analysis software, obtaining approval from the U.S. Food and Drug Administration (FDA) and CE certification in Europe.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230816768554/en/

CONTACT

Heuron Co., Ltd.

Susan Jung

+82-70-4419-0875

susan.j@iheuron.com

Soo-Kyoung Kim

+82-70-4414-8819

skkim@iheuron.com

同じカテゴリーの記事 

  • European Medicines Agency Accepts Deciphera’s Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)
  • JCR Pharmaceuticals Highlights Innovative Gene Therapy Research at the 7th International Forum of Lysosomal Disorders
  • Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance
  • ベイジーン、アーロン・ローゼンバーグ氏を最高財務責任者に任命
  • ICH and CDISC Collaborate to Support the Maintenance and Governance Process for ICH M11 Controlled Terminology